Harmony Biosciences Holdings (HRMY) Stock Price

Harmony Biosciences Holdings Price

NASDAQ·CLOSED
32.59
​
Market closed

Revenue has compounded at 129.2% per year over the past 6 years to 868.45 M USD. Earnings per share have grown at 47.3% per year over the last 4 years. Harmony Biosciences Holdings's net margin stands at 18.3%, up from 11.3% several years earlier. Analysts set a median price target of 39.00 USD, implying 19.7% above the current price. Of 18 analysts, 13 rate the stock a buy — an overall Buy consensus.

Harmony Biosciences Holdings stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harmony Biosciences Holdings business model & stock analysis

Harmony Biosciences Holdings Inc is a US-based company specialized in the development and marketing of innovative therapies and treatments for neurological disorders. The company was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Harmony Biosciences' business model is based on the development of drugs specifically designed to treat sleep disorders and other neurological diseases. The company is a leader in research and development of new compounds in this field and collaborates closely with leading research institutes and experts in the field of sleep medicine. Harmony Biosciences' products are divided into various categories, including narcolepsy, sleep apnea, and other sleep-related disorders. Some of the most well-known products include Pitolisant and Wakix, which are used to treat narcolepsy and EDS. Pitolisant has been approved by the European Medicines Agency and is the first and only drug approved for the treatment of type 1 narcolepsy. Harmony Biosciences heavily invests in research and development of new technologies and approaches to treat sleep disorders and other neurological diseases. The company maintains a strong network of partnerships and collaborations with leading institutes and experts in the field. The goal is to develop new drugs and therapies that improve the quality of life for patients with sleep disorders and other neurological diseases. In addition to drug development, Harmony Biosciences' employees are actively involved in educating and raising awareness about sleep disorders and their impact on health. The company informs and advises patients and their families about various treatment options and actively works on developing new technologies and approaches to improve the diagnosis and treatment of neurological diseases. Overall, Harmony Biosciences aims to improve the quality of life for millions of patients with sleep disorders and other neurological diseases. The company focuses on strategic and collaborative research and development of new technologies and approaches for treating these conditions. With its team of experts and scientists, Harmony Biosciences upholds high standards in research and follows the strict criteria of the medical device industry to develop innovative therapies and medications that will improve the lives of patients worldwide.

Frequently asked questions about Harmony Biosciences Holdings

The business model of Harmony Biosciences Holdings Inc revolves around discovering, developing, and delivering innovative therapies for patients with sleep and central nervous system disorders. With a focus on improving the lives of individuals living with narcolepsy, the company specializes in developing and commercializing treatment options that address the unmet medical needs of this patient population. By leveraging scientific expertise and strategic partnerships, Harmony Biosciences aims to provide effective solutions, fostering better sleep health and overall well-being for those affected by sleep-related disorders. Harmony Biosciences Holdings Inc is committed to driving positive patient outcomes through its dedicated efforts in the field of sleep medicine.

Harmony Biosciences Holdings Inc is primarily active in the pharmaceutical industry.

The main competitors of Harmony Biosciences Holdings Inc in the market are pharmaceutical companies such as Jazz Pharmaceuticals, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. They operate in the same industry and offer similar products and services. These competitors also focus on developing and commercializing therapies for sleep and central nervous system disorders, just like Harmony Biosciences Holdings Inc. It is essential for Harmony Biosciences to constantly innovate and differentiate itself from these competitors to maintain a strong position in the market.

Harmony Biosciences Holdings Inc is a pharmaceutical company focused on developing and commercializing innovative therapies to address sleep and central nervous system disorders. Founded in 2017, Harmony Biosciences aims to improve the lives of patients with unmet medical needs through the advancement of science and compassionate care. The company's primary product, Pitolisant, is the first and only medication approved by the FDA for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Harmony Biosciences is committed to providing effective solutions for patients suffering from sleep-related disorders and has rapidly gained recognition in the biopharmaceutical industry.

Harmony Biosciences Holdings Inc has achieved several significant milestones. The company successfully launched its flagship product, Wakix® (pitolisant), a medication for the treatment of narcolepsy, in the United States. Harmony Biosciences Holdings Inc also received approval from the U.S. Food and Drug Administration (FDA) for the expanded use of Wakix® in treating excessive daytime sleepiness associated with both obstructive sleep apnea and narcolepsy. Additionally, the company secured partnerships and collaborations to enhance research and development efforts. Harmony Biosciences Holdings Inc continues to strive for advancements in treating sleep-wake disorders, making notable strides in improving the lives of patients worldwide.

Harmony Biosciences Holdings Inc is primarily present in the United States.

Harmony Biosciences Holdings Inc represents a commitment to improving the lives of patients with rare neurological disorders. The company's corporate philosophy centers around providing innovative treatment solutions and fostering collaboration within the healthcare community. By prioritizing patient needs, Harmony Biosciences focuses on developing and commercializing therapies that address unmet medical needs. With a strong emphasis on research and development, the company aims to bring transformative therapies to individuals with sleep and central nervous system disorders. Harmony Biosciences Holdings Inc strives to enhance patient outcomes by delivering novel treatment options and advancing the understanding of these conditions.

Analysts currently set an average price target of 46.20 USD for the Harmony Biosciences Holdings stock (median: 39.00 USD), implying +41.8 % versus the latest price. The consensus is based on 18 analyst ratings.

18 analysts currently rate the Harmony Biosciences Holdings stock: 13 recommend buying, 4 holding and 1 selling. For 2026, analysts expect Harmony Biosciences Holdings to generate revenue of 1.03 B USD and earnings per share of 3.57 USD.

Converted at the current exchange rate, the Harmony Biosciences Holdings share trades at 29.70 EUR (32.59 USD).

The Harmony Biosciences Holdings share (HRMY) is listed on 1 stock exchanges, including: NASDAQ (HRMY).

Harmony Biosciences Holdings Inc is a leading provider of innovative therapies and products for the treatment of sleep disorders and other neurological diseases. The company is based in Plymouth Meeting, Pennsylvania, and has been operating since 2016. The business model of Harmony Biosciences is focused on providing effective and long-lasting relief of symptoms for patients with sleep disorders and their consequences. To this end, the company has developed a wide range of products that can be prescribed by doctors and clinics for the treatment of sleep disorders. These include medications such as Pitolisant, used for the treatment of narcolepsy, or Wakix, used for the treatment of excessive daytime sleepiness (EDS) in narcolepsy. Harmony Biosciences specializes not only in the development of medications and therapies, but also offers comprehensive support for the treatment of patients with sleep disorders. A wide network of medical professionals, including doctors, neurologists, and sleep specialists, is available to assist patients in the prevention and treatment of sleep disorders. The company has also invested in the field of medical devices to develop innovative products such as wearable devices for monitoring sleep patterns. These devices capture measurements such as breathing rate, heart rate, movement patterns, and snoring to help assess sleep quality and improve the treatment of sleep disorders. In addition to developing and marketing medications and medical devices, Harmony Biosciences specializes in collaborating with other companies. The company has already formed numerous partnerships with other companies in the field of sleep medicine to jointly discover innovative solutions for the treatment of sleep disorders. In the future, the company plans to further expand its business and drive the development of new products. This includes further improving its medications and medical devices, as well as expanding its network of medical professionals and partners. Overall, Harmony Biosciences Holdings Inc's business model has the potential to remain a key player in the sleep medicine market and make a significant contribution to improving the treatment of sleep disorders.

The expected revenue of Harmony Biosciences Holdings is 1.03 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Harmony Biosciences Holdings is 209.52 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Harmony Biosciences Holdings is currently 9.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harmony Biosciences Holdings stock.

The price-to-sales ratio (P/S) of Harmony Biosciences Holdings is currently 1.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harmony Biosciences Holdings stock.

The Eulerpool Quality Score for Harmony Biosciences Holdings is 7/10.

The ISIN of Harmony Biosciences Holdings is US4131971040. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Harmony Biosciences Holdings is A2QBSF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Harmony Biosciences Holdings is HRMY. The ticker symbol is used to trade Harmony Biosciences Holdings shares on the stock exchange.

Fair ValueTerminal
33.24 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
2.96 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Currency
USD
Initial public offering
Aug 19, 2020
ISIN
US4131971040
Cusip
413197104
Sedol
BKSGZN7
Market capitalization
1.88 B USDSmall Cap
52-Week Range
PEG
1.63
P/E ratio
P/Ee 2026
8.96
P/Ee 2027
8.26
P/Ee 2028
7.24
P/Ee 2029
5.19
P/Ee 2030
6.27
P/S
P/Se
1.86
EV/EBIT
6.54
P/B Ratio
2.16
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
14.30 %
Last updated Nov 22, 2026, 3:39 AM

Harmony Biosciences Holdings Ticker

NASDAQ · HRMY

Harmony Biosciences Holdings FIGI

HRMY:US · BBG00WBPG4C2HRMY:UA · BBG00WBPG4D1HRMY:UC · BBG00WBPG4F9HRMY:UN · BBG00WBPG4H7HRMY:UP · BBG00WBPG4J5HRMY:UQ · BBG00WBPG4K3HRMY:UB · BBG00WBPG4L2HRMY:UM · BBG00WBPG4N0HRMY:UX · BBG00WBPG4P8HRMY:UD · BBG00WBPG4V1HRMY:UF · BBG00WBPG4Y8HRMY:VY · BBG00WBPG4Z7